MTOR and neoplasm: The existence of Trk that may trigger tumor resistance to rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), has been demonstrated in vivo [32], and the systemic application of rapamycin has achieved similar neuroprotective effects to the present data [19,21], supporting the importance of a signal transduction pathway.